Abstract
We estimated the predictive values of activated protein C resistance in the diagnosis of women who are carriers of factor V Leiden. When the prevalence of factor V Leiden is 2%, the positive predictive value is 44% and the cost of preventing one thromboembolic death is $44,180,000. Thus the activated protein C resistance assay is not cost-effective in ruling out factor V Leiden in this population.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bayes Theorem
-
Contraceptives, Oral / administration & dosage
-
Cost-Benefit Analysis / economics
-
Drug Resistance / genetics
-
Factor V / analysis*
-
Female
-
Heterozygote
-
Humans
-
Mass Screening
-
Predictive Value of Tests
-
Protein C*
-
Reagent Kits, Diagnostic / economics
-
Thrombosis / economics
-
Thrombosis / genetics
-
Thrombosis / prevention & control*
Substances
-
Contraceptives, Oral
-
Protein C
-
Reagent Kits, Diagnostic
-
factor V Leiden
-
Factor V